The restored ECM environment regulated the cellular profile
[31] A large study found that GLP-1 RA use was associated with lower risk of developing immune-mediated inflammatory diseases in patients with type 2 diabetes or obesity, suggesting a potential protective effect in some cohorts.[42] What the science is showing is potential for improvements: GLP-1RAs reduce blunt activation in fibroblast-like synoviocytes and improve joint inflammation and metabolic parameters in rheumatoid arthritis models and small human cohorts.[26][29][25] [31] Early clinical studies and case series in RA patients (especially those with coexisting type 2 diabetes or obesity) reported reduced disease activity scores (DAS28), lower C-reactive protein and erythrocyte sedimentation rate levels, fewer swollen joints, and diminished morning stiffness during GLP-1RA treatment, along with the expected weight reduction and improved insulin sensitivity.[31] Psoriasis showed improved PASI scores and quality-of-life metrics in patients with T2DM and psoriasis, alongside reductions in lesional skin and peripheral TNF-producing monocytes.[26] Case series show meaningful skin improvement.[26] In psoriasis and psoriatic arthritis , GLP-1RA therapy has been associated with improvements in inflammatory markers and disease severity indices
"Think squats, lunges, deadlifts, hip hinge variations, rows, presses and carries ," says Davies
The model uses patient-level simulation to capture disease complexity and brings novel approaches to long-standing modeling challenges in T2D, including use of model averaging to estimate the risk of specific complications (where the average of multiple risk equations derived from different populations is applied, with higher weight given to equations derived in populations that more closely match the characteristics of each sampled patient) and modeling the progression of CKD based on mapping of eGFR to KDIGO stages 15, with kidney failure defined as KDIGO stage 5
Sappl et al., 2004, 2009)
Hathcock, John N., and Andrew Shao
